Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05308953




Registration number
NCT05308953
Ethics application status
Date submitted
15/03/2022
Date registered
4/04/2022
Date last updated
10/01/2024

Titles & IDs
Public title
A Phase I Safety Study of NVG-291 in Healthy Adults
Scientific title
A Randomized, Triple-Blind, Placebo-Controlled Phase I Study of Single and Multiple Ascending Doses of NVG-291 in Healthy Subjects
Secondary ID [1] 0 0
NVG-291-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Injuries and Accidents 0 0 0 0
Fractures
Injuries and Accidents 0 0 0 0
Other injuries and accidents
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - NVG-291
Other interventions - Placebo

Experimental: NVG-291 SAD - Doses will begin at the lowest dose level in Cohort 1, increasing in dose with each subsequent cohort to the highest dose level in Cohort 6 or until a maximum tolerated dose (MTD) is reached.

Experimental: NVG-291 MAD - Participants will receive 1 dose daily for for 14 consecutive days. The maximum starting dose for MAD will be 2 dose levels lower than the maximum dose achieved during SAD. There will be a maximum of 3 dosing cohorts in Part 2. The maximum daily dose in Part 2 will not exceed the maximum daily dose tolerated in Part 1.

Experimental: NVG-291 MAD - Males and Premenopausal Females - Participants will receive 1 dose daily for for 14 consecutive days. The dose maximum daily dose in Part 3 will not exceed the maximum daily dose tolerated in either Part 1 or 2.


Treatment: Drugs: NVG-291
NVG-291 is a drug injected under the skin (subcutaneous).

Other interventions: Placebo
Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse Events
Timepoint [1] 0 0
Assessed through 7 days following the last dose of study drug
Secondary outcome [1] 0 0
Pharmacokinetic analysis (plasma)
Timepoint [1] 0 0
Assessed on Day 1 (SAD and MAD) and Day 14 (MAD only)
Secondary outcome [2] 0 0
Immunogenicity analysis
Timepoint [2] 0 0
Assessed on Day 1 (SAD and MAD), Day 8 (SAD and MAD) and Day 21 (MAD only)

Eligibility
Key inclusion criteria
1. Healthy subjects between 18 and 65 years old.

2. BMI between 18 and 33 kg/m2, inclusive, and a total body weight > 50 kg.

3. All laboratory values must be within normal limits or any abnormalities deemed not
clinically significant.

4. All subjects must be willing to abstain from sexual intercourse or to use adequate
contraception during the study and for an additional 120 days after the follow-up
visit.

5. Subjects must not donate ova or sperm during the study and for an additional 120 days
after the follow-up visit

6. Subjects must be willing and able to comply with scheduled visits, all sample
collections, and other trial procedures.

7. Subjects must provide written informed consent.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. For premenopausal female subjects: Irregular menstrual cycles; Amenorrhea; or Abnormal
vaginal bleeding

2. A history (within the past year) or presence of a clinically significant infectious
disease or hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory,
immunologic, hematologic, dermatologic, neurologic, or psychiatric abnormality.

3. Blood pressure > 160/95 at screening or on Day -1.

4. Any active or uncontrolled infections or other medical condition or circumstance that
could interfere with the subject's participation in the study.

5. History of allergic reaction to mannitol.

6. Presence of a tattoo, piercing, scar, or other dermatologic abnormality at the
injection site (abdomen), that might interfere with the ability to assess injection
site reactions

7. a significant history of atopic dermatitis as an adult, or history of severe allergic
reaction to injections.

8. INR > 1.4 or PTT > 50 or platelets <50x10^3/µL at screening or on Day -1.

9. History of regular alcohol consumption exceeding 10 units/week (1 unit = 83 mL of 12%
wine) within 6 months of screening.

10. Test positive for use of drugs or alcohol at screening.

11. Positive hepatitis B, hepatitis C, or HIV test at screening.

12. Blood or plasma donation within 1 week prior to Day -1.

13. Receipt of an investigational drug within 30 days or five half-lives of the drug
(whichever is longer) prior to Day -1.

14. Prior participation in this trial.

15. Female subjects who are breastfeeding or who have a positive pregnancy test at
screening or Day -1.

16. History of any condition that might impair the subject's ability to understand or to
comply with the requirements of the study or to provide informed consent.

17. Receipt of a COVID-19 vaccination within 3 weeks prior to Day -1

18. Subject is at risk of self-harm or harm to others as evidenced by past suicidal
behavior or endorsing items 4 or 5 on the Columbia-Suicide Severity Rating Scale at
screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/05/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
3/07/2023
Sample size
Target
Accrual to date
Final
74
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Networks - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
NervGen Pharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Daniel Miko, MD
Address 0 0
CMO
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/ct2/show/NCT05308953